On January 31, 2024, Chief Medical Officer Karen Noblett executed a sale of 11,288 shares of Axonics Inc (NASDAQ:AXNX). The transaction was filed with the SEC and can be viewed through the SEC Filing. This sale is part of a series of insider transactions by the insider over the past year, which cumulatively amount to 35,287 shares sold and no shares purchased.

• Warning! GuruFocus has detected 6 Warning Signs with GNRC.

Axonics Inc, the company in question, is a medical technology firm that specializes in developing and commercializing novel implantable sacral neuromodulation (SNM) devices for patients with urinary and bowel dysfunction. The company's innovative products are designed to improve the quality of life for patients affected by these conditions.

The insider transaction history for Axonics Inc reveals a pattern of insider selling activity. Over the past year, there have been no insider buys but a total of 15 insider sells. This trend is illustrated in the following insider trend image:

On the valuation front, Axonics Inc's shares were trading at $67.74 on the day of the insider's recent sale, resulting in a market capitalization of $3.434 billion. The stock's price relative to its intrinsic value, as estimated by GuruFocus, indicates that it is Significantly Undervalued. The price-to-GF-Value ratio stands at 0.65, with the GF Value calculated at $105.01 per share.

The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. Additionally, a GuruFocus adjustment factor is applied based on the company's historical returns and growth, along with future business performance estimates provided by Morningstar analysts. The GF Value image below provides a visual representation of this valuation:

The insider's recent transaction adds to the data points that market observers may consider when assessing the stock's performance and insider sentiment. As always, insider transactions are just one factor to consider when evaluating a company's financial health and investment potential.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This article first appeared on GuruFocus.